Zhejiang Medicine unveils new restricted stock incentive plan

Zhejiang Medicine Co., Ltd. has launched its 2025 restricted stock incentive plan, proposing to grant 10.284 million restricted shares. This represents 1.0694% of the company's total share capital. The shares will be sourced from the company's A-share repurchases on the secondary market. The offering price for these restricted shares is set at CNY 7.30 per share.

The plan targets 875 individuals, including the company's directors, senior management, and core employees, excluding independent directors and major shareholders. The restricted shares will be subject to a vesting period of 12 months and 24 months, with 50% of the shares becoming eligible for release in each period. The total duration of the plan will not exceed 36 months from the registration date of the restricted shares.

The estimated total cost of the incentive plan is CNY 73.3249 million, which will be amortized from 2025 to 2027. The projected amortization for 2025 is CNY 4.4033 million, followed by CNY 34.4608 million in both 2026 and 2027. These costs are expected to impact the company's net profit during the plan's validity.